The company received a CE Mark (European Conformity approval) for the Ulthera System in 2007 and is expecting FDA clearance to sell products in the US. Ulthera will use funds to commercialize its technology globally, conduct additional product development and execute more clinical studies to support expanded use of its platform.
Matt Likens, president and CEO of Ulthera, said: “Clearly the company will benefit from this substantial capital infusion but we will benefit just as much from the support that NEA and our series A investor, 3i, can provide.”